PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26810188-9	2016	Mechanistically, niclosamide treatment in combination with or without cisplatin significantly inhibited Akt, ERK, and Src signaling pathways.	Niclosamide	17-28	mitogen-activated protein kinase 1	Homo sapiens	109-112	
30651927-11	2018	These results suggest that uncouplers such as SR4 and niclosamide may be useful as first line treatment against melanoma regardless of BRAF/NRAS status, and as an adjuvant therapy for patients failing MAPK inhibitors.	Niclosamide	54-65	mitogen-activated protein kinase 1	Homo sapiens	201-205	
35008910-0	2022	Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway.	Niclosamide	0-11	mitogen-activated protein kinase 1	Homo sapiens	113-116	
35008910-10	2022	Therefore, TGFBI derived from osteosarcoma cells via the ERK pathway contributed to cellular migration and invasion and niclosamide inhibited these processes.	Niclosamide	120-131	mitogen-activated protein kinase 1	Homo sapiens	57-60	
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	mitogen-activated protein kinase 1	Homo sapiens	73-76